Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach

Gorbalenya, 2020, Severe acute respiratory syndrome-related coronavirus: the species and its viruses – a statement of the Coronavirus Study Group, bioRxiv Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, 56, 10.1016/j.ijantimicag.2020.105949 Chan, 2015, Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease, Clin Microbiol Rev, 28, 465, 10.1128/CMR.00102-14 Muralidharan, 2020, Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19, J Biomol Struct Dyn, 39, 2673, 10.1080/07391102.2020.1752802 Khan, 2020, Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach, J Biomol Struct Dyn, 39, 2607, 10.1080/07391102.2020.1751298 Elfiky, 2020, Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study, Life Sci, 253, 10.1016/j.lfs.2020.117592 Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, 56, 10.1016/j.ijantimicag.2020.105949 Wang, 2020, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, 30, 269, 10.1038/s41422-020-0282-0 Gao, 2020, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci. Trends, 14, 72, 10.5582/bst.2020.01047 Yao, 2020, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, 71, 732, 10.1093/cid/ciaa237 Tam, 2021, Computational estimation of potential inhibitors from known drugs against the main protease of SARS-CoV-2, RSC Adv, 11, 17478, 10.1039/D1RA02529E Zumla, 2016, Coronaviruses—drug discovery and therapeutic options, Nat Rev Drug Discov, 15, 327, 10.1038/nrd.2015.37 Yalçın, 2021, In silico detection of inhibitor potential of Passiflora compounds against SARS-Cov-2 (Covid-19) main protease by using molecular docking and dynamic analyses, J Mol Struct, 1240, 10.1016/j.molstruc.2021.130556 Bhardwaj, 2021, Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors, J Biomol Struct Dyn, 39, 3449, 10.1080/07391102.2020.1766572 Bhardwaj, 2021, Bioactive molecules of Tea as potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2, Front Med, 8 Bhardwaj, 2021, Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs, Comput Biol Med, 128, 10.1016/j.compbiomed.2020.104117 Singh, 2021, In-silico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors, J. Tradit. Compl. Med Sharma, 2021, An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2, Food Chem, 346, 10.1016/j.foodchem.2020.128933 Singh, 2021, A computational approach for rational discovery of inhibitors for non-structural protein 1 of SARS-CoV-2, Comput Biol Med, 10.1016/j.compbiomed.2021.104555 Hussien, 2020, Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease, Netw, 9, 1 Kalhor, 2020, Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches, J Biomol Struct Dyn, 1 Yuan, 2020, Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system, Pharmacol Res, 159, 10.1016/j.phrs.2020.104960 Food, 2020 Nguyen, 2020, Remdesivir strongly binds to both RNA-dependent RNA polymerase and main protease of SARS-CoV-2: evidence from molecular simulations, J Phys Chem B, 124, 11337, 10.1021/acs.jpcb.0c07312 Marmor, 2016, Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision), Ophthalmology, 123, 1386, 10.1016/j.ophtha.2016.01.058 Yao, 2020, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, 71, 732, 10.1093/cid/ciaa237 Baildya, 2020, Inhibitory activity of hydroxychloroquine on COVID-19 main protease: an insight from MD-simulation studies, J Mol Struct, 1219, 10.1016/j.molstruc.2020.128595 Beura, 2020, In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2, J Biomol Struct Dyn, 11, 28876 Trott, 2010, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J Comput Chem, 31, 455, 10.1002/jcc.21334 Singh, 2017, Evaluation of protein-ligand docking methods on peptide-ligand complexes for docking small ligands to peptides, BioRxiv Prasanth, 2020, In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2, J Biomol Struct Dyn, 1 Berendsen, 1995, GROMACS: a message-passing parallel molecular dynamics implementation, Comput Phys Commun, 91, 43, 10.1016/0010-4655(95)00042-E Abraham, 2015, GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers, SoftwareX, 1, 19, 10.1016/j.softx.2015.06.001 Bjelkmar, 2010, Implementation of the CHARMM force field in GROMACS: analysis of protein stability effects from correction maps, virtual interaction sites, and water models, J Chem Theor Comput, 6, 459, 10.1021/ct900549r Vanommeslaeghe, 2010, CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields, J Comput Chem, 31, 671, 10.1002/jcc.21367 Zoete, 2011, SwissParam: a fast force field generation tool for small organic molecules, J Comput Chem, 32, 2359, 10.1002/jcc.21816 Jorgensen, 1983, Comparison of simple potential functions for simulating liquid water, Int. J. Chem. Phys, 79, 926, 10.1063/1.445869 Darden, 1993, Particle mesh Ewald: an N⋅ log (N) method for Ewald sums in large systems, Int. J. Chem. Phys, 98, 10089, 10.1063/1.464397 Kumari, 2014, Consortium OSDD, Lynn A. g_mmpbsa– A GROMACS tool for high-throughput MM-PBSA calculations, J Chem Inf Model, 54, 1951, 10.1021/ci500020m Vardhan, 2020, In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19, Comput Biol Med, 124, 10.1016/j.compbiomed.2020.103936 García-Fernández, 2016, Two variants of the major serine protease inhibitor from the sea anemone Stichodactyla helianthus, expressed in Pichia pastoris, Protein Expr. Purif, 123, 42, 10.1016/j.pep.2016.03.003 Verma, 2020 Mohammadi, 2020, In silico investigation on the inhibiting role of nicotine/caffeine by blocking the S protein of SARS-CoV-2 versus ACE2 receptor, Microorganisms, 8, 1600, 10.3390/microorganisms8101600 Wanga N, Hana S, Liua R, Mengb L, Hea H, Zhanga Y, et al. Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of COVID-19 Spike pseudotype virus. Imai, 2008, The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice, Exp Physiol, 93, 543, 10.1113/expphysiol.2007.040048 Hasan, 2021, Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: a drug repurposing and molecular docking approach, Biomed Pharmacother, 140, 10.1016/j.biopha.2021.111742 Bryson, 2009, Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers, Br J Clin Pharmacol, 67, 309, 10.1111/j.1365-2125.2008.03311.x Rickards, 1949, The treatment of amoebiasis with" Diodoquin", Am. J. Trop, 52, 33 Padwal, 2008, Cetilistat, a new lipase inhibitor for the treatment of obesity, Curr Opin Invest Drugs, 9, 414 Cheung, 2020, Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis, Gastroenterology, 159, 81, 10.1053/j.gastro.2020.03.065 Chan, 2020, Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility, Clin Infect Dis, 71, 2428, 10.1093/cid/ciaa644 Cheng, 2007, Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection, Clin Microbiol Rev, 20, 660, 10.1128/CMR.00023-07 Hung, 2004, Viral loads in clinical specimens and SARS manifestations, Emerg Infect Dis, 10, 1550, 10.3201/eid1009.040058 Boehm, 1995, Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells, J Med Chem, 38, 3146, 10.1021/jm00016a018 Gniadecki, 2007, The optimal use of bexarotene in cutaneous T-cell lymphoma, Br J Dermatol, 157, 433, 10.1111/j.1365-2133.2007.07975.x Dragnev, 2007, A proof-of-principle clinical trial of bexarotene in patients with non–small cell lung cancer, Clin Canc Res, 13, 1794, 10.1158/1078-0432.CCR-06-1836 Esteva, 2003, Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer, J Clin Oncol, 21, 999, 10.1200/JCO.2003.05.068 Duc, 2003, In vitro and in vivo models for the evaluation of potent inhibitors of male rat 17α-hydroxylase/C17, 20-lyase, J Steroid Biochem Mol Biol, 84, 537, 10.1016/S0960-0760(03)00078-5 Arasaratnam, 2019, Inter-and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer, Canc. Chemother. Pharmacol, 84, 139, 10.1007/s00280-019-03862-x Yuan, 2019, SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target, Nat Commun, 10, 1, 10.1038/s41467-018-08015-x Erva, 2016, Molecular dynamic simulations of Escherichia coli L-asparaginase to illuminate its role in deamination of asparagine and glutamine residues, 3 Biotech, 6, 2, 10.1007/s13205-015-0339-9 Priya, 2015, Molecular docking and molecular dynamics to identify a novel human immunodeficiency virus inhibitor from alkaloids of Toddalia asiatica, 11, S414 Basit, 2021, Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent, J Biomol Struct Dyn, 39, 3605, 10.1080/07391102.2020.1768150